Press releases
- Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
- Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
- Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
- Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
- Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
- Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
More ▼
Key statistics
As of last trade Marinus Pharmaceuticals Inc (0JYL:LSE) traded at 1.18, 2.67% above its 52-week low of 1.15, set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 1.18 |
Low | 1.18 |
Bid | -- |
Offer | -- |
Previous close | 1.18 |
Average volume | 10.28k |
---|---|
Shares outstanding | 54.93m |
Free float | 54.31m |
P/E (TTM) | -- |
Market cap | 66.47m USD |
EPS (TTM) | -2.64 USD |
Data delayed at least 20 minutes, as of Jul 02 2024 18:24 BST.
More ▼